Loading
CD209 (CD209 antigen) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Gastric & gastro-oesophageal junction cancer and Non-small-cell lung cancer.
Pathogen-recognition receptor expressed on the surface of immature dendritic cells (DCs) and involved in initiation of primary immune response. Thought to mediate the endocytosis of pathogens which are subsequently degraded in lysosomal compartments. The receptor returns to the cell membrane surface and the pathogen-derived antigens are presented to resting T-cells via MHC class II proteins to initiate the adaptive immune response.
IntOGen calls it a driver in 3 cohorts (2 activating, 1 loss-of-function), covering Invasive Breast Carcinoma, Lung Squamous Cell Carcinoma, Stomach Adenocarcinoma.
In plain words · CD209 (CD209 antigen) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Gastric & gastro-oesophageal junction cancer and Non-small-cell lung cancer.
CD209 (CD209 antigen) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Gastric & gastro-oesophageal junction cancer and Non-small-cell lung cancer.
Pathogen-recognition receptor expressed on the surface of immature dendritic cells (DCs) and involved in initiation of primary immune response.
No product in this corpus aims at CD209 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
First described 1992. Earliest sequence paper UniProt cites for the protein: Curtis B.M. et al, Proc. Natl. Acad. Sci. U.S.A, 1992, "Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp 120". Source.
Sources: HGNC HGNC:1641 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9NNX6 (protein name, function text, keywords and locations (REST API)); IntOGen CD209 (driver in 3 cohorts (Act 2, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Pathogen-recognition receptor expressed on the surface of immature dendritic cells (DCs) and involved in initiation of primary immune response. Thought to mediate the endocytosis of pathogens which are subsequently degraded in lysosomal compartments. The receptor returns to the cell membrane surface and the pathogen-derived antigens are presented to resting T-cells via MHC class II proteins to initiate the adaptive immune response. On dendritic cells (DCs) it is a high affinity receptor for ICAM2 and ICAM3 by binding to mannose-like carbohydrates. May act as a DC rolling receptor that mediates transendothelial migration of DC presursors from blood to tissues by binding endothelial ICAM2. Forms a first contact between DC and resting T cell, througth ICAM3 binding, facilitating the downstream DC-T cell clustering process and DC-induced proliferation of resting T Cells. Location: Membrane raft; Cell membrane; Secreted (UniProt). Locus 19p13.2 (HGNC).
Query for this target: (TITLE:"CD209" OR ABSTRACT:"CD209" OR TITLE:"CD209 molecule" OR ABSTRACT:"CD209 molecule" OR TITLE:"CD209 antigen" OR ABSTRACT:"CD209 antigen" OR TITLE:"DC-SIGN" OR ABSTRACT:"DC-SIGN" OR TITLE:"hDC-SIGN" OR ABSTRACT:"hDC-SIGN" OR TITLE:"CDSIGN" OR ABSTRACT:"CDSIGN") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD209, not a curated reading list.